[Clinical studies of cefpodoxime proxetil in respiratory tract infections].
Twelve patients with respiratory tract infections were treated with cefpodoxime proxetil (CS-807, CPDX-PR), a new cephem antibiotic. It was given orally at a dose of 200 mg 2 times a day for 4 approximately 15 days. Its clinical effects were evaluated as excellent in 1 case, good in 9 cases and poor in 2 cases. The efficacy rate was 83.3%. Its bacteriological effects were evaluated as eradication in 5 strains and decrement in 1 strain. The eradication rate was 83.3%. No adverse reactions and disorder of laboratory findings due to CPDX-PR were observed.
Odagiri
S
S
Department of Respiratory Disease, Kanagawa Prefectual Nagahama Hospital.
Matsunaga
K
K
Suzuki
K
K
Murohashi
K
K
Takahashi
H
H
Numata
H
H
Takahashi
K
K
Yamaki
I
I
Ishii
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001987:Bronchiectasis / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D002511:Cephalosporins; D000097627:Cefpodoxime Proxetil